Delivery Order SPE2DB22D3009-SPE2DB23FAW66
Award Date 9/8/23
Potential Completion Date 9/29/23
Potential Value $10K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency issued a $8,351.42 delivery order to AmerisourceBergen Drug Corp on April 7, 2026, for IMBRUVICA 140 MG capsules (90-count units). The order is placed under the DLA Troop Support Medical Indefinite Delivery Contract (valued at $999,999,999.00 through December 2026), which supplies pharmaceutical products and medical commodities to support military healthcare programs globally. Place of performance is Conshohocken, PA. The order carries a firm fixed price structure...
- The Defense Logistics Agency issued a $16,702.84 delivery order to Amerisourcebergen Drug Corp on March 9, 2026, for IMBRUVICA 140 MG capsules (90-count units), with an ultimate completion date of March 30, 2026. The order is issued under the DLA Troop Support Medical indefinite delivery contract (SPE2DX), a $999,999,999 vehicle through December 2026 that supplies pharmaceutical products and medical supplies to support military healthcare programs worldwide. Place of performance is Conshohocken,...
- The Defense Logistics Agency issued a $16,702.84 delivery order to AmerisourceBergen Drug Corp on March 9, 2026, for IMBRUVICA 140 mg capsule (90-count units) with an ultimate completion date of March 30, 2026. The order is issued under the DLA Troop Support Medical IDC (SPE2DX), a $999,999,999 indefinite delivery contract through December 2026 that supplies pharmaceutical products and medical supplies to support military healthcare programs globally. Place of performance is Conshohocken, PA....
- The Defense Logistics Agency awarded a $10,460.95 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 120 capsules of IMBRUVICA 140 MG to be delivered to their Conshohocken, Pennsylvania facility. Amerisourcebergen will supply the pharmaceutical products to the DLA under this order, which has a period of performance from July 10, 2023 through July 31, 2023. As a major component of the Department of Defense that manages global logistics operations for the military...
- The Defense Logistics Agency issued a $7,793.26 delivery order to Amerisourcebergen Drug Corp on March 17, 2026, for IMBRUVICA 280 mg tablets. The order is issued under the company's Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999 through December 2026, which provides pharmaceutical and medical supplies for military healthcare programs globally. Place of performance is Conshohocken, PA. The order is firm fixed price with an ultimate completion date of...
- The Defense Logistics Agency issued a $8,351.42 delivery order to Amerisourcebergen Drug Corp on March 5, 2026, for IMBRUVICA 140 MG capsules (90 count). The order is issued under the DLA Troop Support Medical Indefinite Delivery Contract (IDC), valued at $999,999,999.00 through December 2026, which provides pharmaceutical and medical supply support to military healthcare systems globally. Place of performance is Conshohocken, PA. The order is firm fixed price with an ultimate completion date of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of IMBRUVICA 140 mg capsules (90-count units) with a ceiling value of $16,233.74. This competitively awarded, firm fixed-price contract has an ultimate completion date of September 10, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office...
- <p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on April 3, 2026, for Imbruvica 140 mg capsules (90-count), with a ceiling value of $8,351.42 and a firm fixed price. The order is due for ultimate completion on April 24, 2026.</p> <p>Place of performance is Conshohocken, PA. The delivery order was issued under no set-aside and carries firm fixed pricing.</p>
- The Defense Logistics Agency issued a $7,793.26 delivery order to AmerisourceBergen Drug Corp on May 4, 2026, for IMBRUVICA 280 MG tablets (28-count packaging). The order carries a firm fixed-price structure with an ultimate completion date of May 26, 2026. Place of performance is Conshohocken, PA. The order was issued under a single-award indefinite delivery contract with the Defense Logistics Agency supporting the Pharmaceutical Prime Vendor Global Program Generation V, which supplies...
- The Defense Logistics Agency issued a $7,794.10 delivery order to Amerisourcebergen Drug Corp on April 8, 2026, for IMBRUVICA 420 mg tablets (28-count). This order is issued under the DLA Troop Support Medical IDC (SPE2DX), a $999,999,999 indefinite delivery contract running through December 2026 that supplies pharmaceutical products and medical supplies to support military healthcare programs globally. Place of performance is Conshohocken, Pennsylvania. The order carries a firm fixed price...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB23FAW66Delivery Order
The Defense Logistics Agency awarded a $10,460.95 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 120 capsules of the pharmaceutical IMBRUVICA 140 MG. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The delivery order has a period of performance starting on September 8, 2023 through September 29, 2023. As the DLA supports the logistical needs of the Department of Defense, this delivery order was likely placed to supply military treatment facilities with a specified quantity of the cancer treatment drug IMBRUVICA during the noted three-week timeframe.
Generated 12/22/23, 1:48 PM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.5k | 9/8/23 |